결핵 진료지침

10. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine-Moxifloxacin Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021;384(18):1705-18.
11. WHO operational handbook on tuberculosis. Module 4: Treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
12. Huynh J, Donovan J, Phu NH, Nghia HDT, Thuong NTT, Thwaites GE. Tuberculous meningitis: progress and remaining questions. Lancet Neurol 2022;21(5):450-64.
13. Dhawan SR, Gupta A, Singhi P, Sankhyan N, Malhi P, Khandelwal N. Predictors of Neurological Outcome of Tuberculous Meningitis in Childhood: A Prospective Cohort Study From a Developing Country. J Child Neurol 2016;31(14):1622-7.
14. Gupta R, Kushwaha S, Thakur R, Jalan N, Rawat P, Gupta P, et al. Predictors of adverse outcome in patients of tuberculous meningitis in a multi-centric study from India. Indian J Tuberc 2017;64(4):296-301.
15. Thee S, Basu Roy R, Blázquez-Gamero D, Falcón-Neyra L, Neth O, Noguera-Julian A, et al. Treatment and outcome in children with tuberculous meningitis – a multi-centre Paediatric Tuberculosis Network European Trials Group study. Clin Infect Dis 2022;75(3):372-81.
16. van Toorn R, Schaaf HS, Laubscher JA, van Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J 2014;33(3):248-52.
17. van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics 2009;123(1):e1-8.
18. Solans BP, Béranger A, Radtke K, Mohamed A, Nahid P, Savic R. Web Annex 1. Clinical outcomes and pharmacokinetics of first-line drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) in children (< 18

VII. 소아청소년 결핵 <PAGE>243